Hepatocellular carcinoma, the most common type of liver cancer, is a critical health problem in the United States and the fifth leading cause of cancer deaths. However, the disease does not affect all groups equally and nobody is really sure why.
Cancer survivors in the U.S. currently number 17 million, with that number expected to climb to 26 million within the next 20 years. As defined by the National Cancer Institute, cancer survivorship care focuses on the health and life of a person following initial treatment through the end of life. It covers the physical, psychosocial, and economic issues of cancer, beyond the diagnosis and initial treatment phases.
Urologic cancer experts at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are leading a clinical trial study for patients with non-muscle invasive bladder cancer (NMIBC) that has failed previous therapy.
In a study recently published in the journal Oncogene, a research team led by Tan Ince, M.D., Ph.D., described the mechanisms that help the gene histone deacetylase (HDAC) 7 control other genes, driving breast cancer and helping maintain cancer stem cells. In addition, the paper showed HDAC7 activity is downstream from other HDAC molecules, particularly HDAC1, possibly making it a better therapeutic target for future
Four renowned oncologists who have been treating cancer patients in this region for many years are joining Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, and South Florida’s only cancer center to achieve the prestigious National Cancer Institute designation.
Dr. Stephen D. Nimer, director of Sylvester Comprehensive Cancer Center, which recently received a prestigious designation from the National Cancer Institute, has been named the inaugural holder of the Oscar de la Renta Endowed Chair in Cancer Research.
Immune therapy has not worked well in pancreatic cancer because of the cancer’s inherent immune resistance. Sylvester Comprehensive Cancer Center scientists have discovered a way to outsmart the deadly cancer’s ability to prevent immune checkpoint inhibitor therapy from killing pancreatic cancer cells.
Researchers at the NCI-designated Sylvester Comprehensive Cancer Center, working within several departments at the University of Miami Miller School of Medicine, have identified another critical component of the AML1-ETO multi-protein complex that could point the way to more effective therapies for acute myeloid leukemia (AML).
A study looking at PARP inhibition in diffuse large B cell lymphoma opens the door to a new way to treat this common type of cancer, according to study author Izidore S. Lossos, M.D., endowed director of the Lymphoma Program at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and head of the Hematological Malignancies Site Disease Group.
Researchers have struggled with the challenge of getting oral medications past the treacherous environment of the gut intact and into the bloodstream where they can be most effective. But now Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine researchers report success in accomplishing this breakthrough using nanotechnology.